Register
Login:
Share:
Email Facebook Twitter




Immupharma Share Price (IMM)



Share Price Information for Immupharma (IMM)


Share Price: 29.50Bid: 29.50Ask: 31.75Change: 0.00 (0.00%)No Movement on Immupharma
Spread: 2.25Spread as %: 7.63%Open: 29.50High: 30.00Low: 29.50Yesterday’s Close: 29.50

Immupharma Plc Ord 10P

Immupharma is listed in the FTSE AIM All-Share
Immupharma is part of the Medicine and Biotech Research sector






Share Price SpacerPrice
29.50

Share Price SpacerBid
29.50

Share Price SpacerAsk
31.75

Share Price SpacerChange
0%0.00

Share Price SpacerVolume
115,608

Share Price SpacerOpen
29.50

Share Price SpacerHigh
30.00

Share Price SpacerLow
29.50

Share Price SpacerClose
29.50

Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 121.78m £36.69m 10,000

52 Week High 50.00 52 Week High Date 5-JUN-2015
52 Week Low 19.75 52 Week Low Date 2-DEC-2015

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
12 19,991 95,617 -8.601 -3.43 0.00 0.00




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

04-May-16
10:44:05
30.70
10,566
Buy* 
29.50
31.75
3,244
Trade Type:
Ordinary

04-May-16
10:38:31
30.6685
500
Buy* 
29.50
31.75
153.34
Trade Type:
Ordinary

04-May-16
10:37:54
29.50
903
Sell* 
29.50
31.75
266.39
Trade Type:
Automatic execution



Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

04-May-16
08:08:33
30.925
25,836
Buy* 
29.00
31.75
7,990
Trade Type:
Ordinary

04-May-16
08:10:57
30.925
25,836
Buy* 
29.00
31.75
7,990
Trade Type:
Ordinary

04-May-16
09:26:24
30.85
15,150
Buy* 
29.50
31.75
4,674
Trade Type:
Ordinary

04-May-16
09:27:25
30.85
15,150
Buy* 
29.50
31.75
4,674
Trade Type:
Ordinary

04-May-16
10:44:05
30.70
10,566
Buy* 
29.50
31.75
3,244
Trade Type:
Ordinary



View more Immupharma trades >>

Directors Deals for Immupharma (IMM)
Trade DateActionNotifierPriceCurrencyAmountHolding
30-Apr-15Notification of Holding
Trade Notifier Information for Immupharma
Stephane Robert George Mery held the position of Non-Executive Director at Immupharma at the time of this trade.
 Stephane Robert George Mery
002259
24-Jan-13Sell
Trade Notifier Information for Immupharma
Ajay Agrawal held the position of Non-Executive Director at Immupharma at the time of this trade.
 Ajay Agrawal
57GBX62,1690
24-Jan-12Buy
Trade Notifier Information for Immupharma
Ajay Agrawal held the position of Non-Executive Director at Immupharma at the time of this trade.
 Ajay Agrawal
80GBX62,1690
View more Immupharma directors dealings >>



Date/TimeAuthorSubjectShare PriceOpinion
Today 14:28jupiternmarsVideo interview with Tim McCarthy29.50No Opinion
http://tinyurl.com/zrqkk59

ImmuPharma PLC (LON:IMM) has begun dosing its first patients in the phase-III trial of its flagship drug Lupuzor for the hard-to-treat autoimmune disease Lupus.
In all 200 people will take part in the study, which is being carried out over 10 centres in the States and 35 in Europe, and Chairman Tim McCarthy tells Proactive Investors recruitment is “going well”.
He expects all the necessary patients to be recruited this year, with the trial to be… Read More
Today 14:12hunkymonkeyAnother interview29.50No Opinion
Today 13:26ThomasTheTankPanmure Gordon note - Research Tree29.50No Opinion
Read Panmure Gordon & Co's note on IMMUPHARMA PLC (IMM), out this morning, by visiting https://www.research-tree.com/company/GB0033711010
"This morning ImmuPharma has released prelims for the year-ending 31 December 2015. Today’s numbers reflect a business in development-phase – the pivotal phase III study for Lupuzor™ now having commenced – with the fund-raising process (£8.4m fundraising and EIS/VCT qualifying status) having been completed after the… Read More
Today 13:11ThomasTheTankNorthland note29.50No Opinion
Read Northland Capital Partners's note on IMMUPHARMA PLC (IMM), out this morning, by visiting https://www.research-tree.com/company/GB0033711010
"ImmuPharma continues to progress its lead clinical programme, with recruitment in the Lupuzor Phase III trial going to plan. The group’s key objective this year is to complete the recruitment of 200 Lupus patients. Top line results from the trial are expected to be announced by the end of 2017..."
Today 07:45hunkymonkeyRns29.50No Opinion
Very interesting line: A new patent has been filed outside of Lupus, which has the potential for Orphan Drug designation

Clearly they are developing lupazor for other auto immune diseases. Could this be slither blockbuster drug?

http://m.londonstockexchange.com/exchange/mobile/news/detail/12802206.html
Fri 20:23hunkymonkeyRE: Massive delayed trade30.125No Opinion
There is absolutely no chance that, the big trade is a sell. This is a really usual share. I bought 60k shares last month and door the rest of the day about 300 x 79 share trades went through.

If kefi goes 1p I'm going well over 100k shares here if still at sub 30p

T

Share prices shown are taken at time of message posting.
Thread ViewThread View
View more share chat for Immupharma (IMM) >>

Please login or register to post a message on Share Chat.






Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk








Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.